Commentary

Video

Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor

Fact checked by:

R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.

"Other models that we've developed include the first genetically inducible mouse model of this disease that relies on an engineered FOXL2 allele, and we think that that is going to really move us forward, as far as having a high-fidelity animal model for the first time, [which] will let us do kinds of investigations that weren't really possible before."

R. Tyler Hillman, MD, PhD, assistant professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, assistant professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor (AGCT) of the ovary.

One of the focuses of Hillman’s lab is to develop new candidates for drug development that can be tested in phase 1/2 clinical trials or provide proof of principle that certain drugs can be repurposed from their use in other diseases. The other focus is on developing a mechanistic understanding of how FOXL2 mutations may cause AGCT tumors, with the hope of uncovering a previously unthought-of pathway toward drug development. As such, Hillman and his collaborators have focused on model development, which has led to the university’s first organoid derivation program for patients with AGCT undergoing surgery. The samples that are collected are used for drug tests and other experimentation, including high-throughput screening. This process led to the discovery that glucocorticoids can stimulate the growth of AGCT cells, but only in the presence of mutations in FOXL2, indicating a true pharmacogenetic effect, Hillman says.

These findings, which were published in Cancer Research in 2024, provided evidence that glucocorticoids as a class stimulated the growth of KGN-FOXL2WT/C402G cells with nanomolar EC50, whereas they lacked this activity in KGN-FOXL2–/– cells. Now, Hillman and his team are investigating ways of modulating glucocorticoid receptor signaling, either through single-agent or combination therapy, which Hillman theorizes will be a chemotherapeutic regimen of some sort. Additional models that have been fully developed include the first genetically inducible mouse model of AGCT, Hillman says. The model relies on an engineered FOXL2 allele and is believed to hold the potential to push the field of drug discovery forward.

Related Videos
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine